Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403

Benzinga · 1d ago
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and lowers the price target from $409 to $403.